Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 448

Sort by

Sort Order Select

Journal Articles

Total Therapy (TT)-4: A Phase 3 Trial Comparing L-TT4 and S-TT4 and Tandem Auto Transplants in Standard Risk Multiple Myeloma

Samer Al Hadidi, Obada Ababneh, Carson W Ercanbrack, Carolina Schinke, Sharmilan Thanendrarajan, Clyde Bailey, Robert Smith, Susan Panozzo, Guido Tricot, Daisy V. Alapat, John D Shaughnessy, Jr, Fenghuang Zhan, Bart Barlogie, Maurizio Zangari, Frits van Rhee

Blood (2023) 142 (Supplement 1): 3594.

https://doi.org/10.1182/blood-2023-181034

Published: 2023

Journal Articles

Sequential Imaging with Diffusion-Weighted Whole-Body MRI (DW-MRI) and PET-CT Identifies Patients at High Risk of Relapse in Multiple Myeloma

Carolina Schinke, Leo Rasche, Cody Ashby, Rudy van Hemert, Sharmilan Thanendrarajan, Samer Al Hadidi, Maurizio Zangari, Clyde Bailey, Daisy V. Alapat, John D Shaughnessy, Jr, Fenghuang Zhan, Bart Barlogie, Frits van Rhee, Niels Weinhold

Blood (2023) 142 (Supplement 1): 882.

https://doi.org/10.1182/blood-2023-180896

Published: 2023

Journal Articles

Impact of Dexamethasone (Dex) Dose Strength on Outcomes in Newly Diagnosed Multiple Myeloma (NDMM): A Secondary Analysis of SWOG Studies S0777 and S1211

Rahul Banerjee, Rachael Sexton, Andrew J. Cowan, Sikander Ailawadhi, S. Vincent Rajkumar, Shaji Kunnathu Kumar, Sagar Lonial, Bart Barlogie, Brian GM Durie, Saad Z Usmani, Antje Hoering, Robert Z. Orlowski

Blood (2023) 142 (Supplement 1): 1066.

https://doi.org/10.1182/blood-2023-181744

Published: 2023

Journal Articles

N-Cadherin Stabilizes β-Catenin and Promotes β-Catenin/TCF Transcriptional Activation and Cell Adhesion-Mediated Drug Resistance in Multiple Myeloma

Shiqiao Ye, Yu Chen, Bo Hu, Huayu Huang, Yuxiao Sun, James P Stewart, Sarah K Johnson, Bart Barlogie, Maurizio Zangari, Guido Tricot, Faith E Davies, Gareth J Morgan, Brian A Walker, Fenghuang Zhan, Frits van Rhee, John D Shaughnessy, Jr., Ya-Wei Qiang

Blood (2021) 138 (Supplement 1): 1572.

https://doi.org/10.1182/blood-2021-148624

Published: 2021

Journal Articles

28-Day Metronomic Therapy for Relapsed Refractory Multiple Myeloma

Tarek H Mouhieddine, MD, Julia Hieulle, Erin Moshier, MS, Josh R. Richter, MD, Hearn Jay Cho, MD PhD, Samir Parekh, MD, Ajai Chari, MD, Bart Barlogie, MD PhD, Sundar Jagannath, MD, Deepu Madduri, MD

Blood (2020) 136 (Supplement 1): 13.

https://doi.org/10.1182/blood-2020-142210

Published: 2020

Journal Articles

The Role of PHF19 As a Promoter of Tumorigenicity and Therapeutic Target in Multiple Myeloma

Carolina D. Schinke, MD, Pingping Qu, Shmuel Yaccoby, PhD, Valeriy V Lyzogubov, MD PhD, Veronica MacLeod, Eileen M Boyle, Randal Shelton, Wen Ling, PhD, Sharmilan Thanendrarajan, MD, Maurizio Zangari, MD, Bart Barlogie, MD PhD, Frits van Rhee, MD PhD, Brian A Walker, PhD

Blood (2019) 134 (Supplement_1): 508.

https://doi.org/10.1182/blood-2019-130595

Published: 2019

Journal Articles

Analysis of the Sub-Clonal Structure of Smoldering Myeloma over Time Provides a New Means of Disease Monitoring and Highlights Evolutionary Trajectories Leading to Myeloma

Eileen M Boyle, MD MSc, Faith E. Davies, MD, Shayu Deshpande, Ruslana G. Tytarenko, MS, Cody Ashby, PhD, Yan Wang, Christopher P. Wardell, PhD MSc, BSc, Michael A Bauer, PhD, Sarah K Johnson, PhD, Carolina D. Schinke, MD, Sharmilan Thanendrarajan, MD, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Louis Williams, MD MBA, Thierry Facon, MD, Charles Dumontet, Bart Barlogie, MD PhD, Gareth Morgan, MDPhDFRCP, Brian A Walker, PhD

Blood (2019) 134 (Supplement_1): 4333.

https://doi.org/10.1182/blood-2019-126679

Published: 2019

Journal Articles

Long-Term Outcome of Total Therapy Regimens: Impact of Molecular Subgroups

Frits van Rhee, MD PhD, Maurizio Zangari, MD, Carolina D. Schinke, MD, Guido J. Tricot, MD PhD, Doug Steward, Susan Panozzo, Jeffery R. Sawyer, Brian A Walker, PhD, Joshua Epstein, DSc, Faith E. Davies, MD, Gareth Morgan, MD PhD, Adam Rosenthal, MS, Antje Hoering, PhD, Katherine K Nishimura, Bart Barlogie, MD PhD

Blood (2019) 134 (Supplement_1): 3309.

https://doi.org/10.1182/blood-2019-131870

Published: 2019

Journal Articles

Lack of a Spleen Signal on Diffusion Weighted MRI Is Associated with High Tumor Burden and Poor Prognosis in Multiple Myeloma

Leo Rasche, Manoj Kumar, MD, Grant Gershner, James E McDonald, BS, MD, Samrat Roy Choudhury, PhD, Rudy L. Van Hemert, MD, Joshua Epstein, DSc, Sharmilan Thanendrarajan, MD, Carolina D. Schinke, MD, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Bart Barlogie, MD PhD, Faith E. Davies, MD, Gareth Morgan, MD, Niels Weinhold, PhD

Blood (2018) 132 (Supplement 1): 4471.

https://doi.org/10.1182/blood-2018-99-119759

Published: 2018

Journal Articles

Global Expression Changes of Malignant Plasma Cells over Time Reveals the Evolutionary Development of Signatures of Aggressive Clinical Behavior

Blood (2018) 132 (Supplement 1): 4457.

https://doi.org/10.1182/blood-2018-99-119113

Published: 2018

Journal Articles

The Mutational Landscape of Primary Plasma Cell Leukemia

Carolina D. Schinke, MD, Cody Ashby, PhD, Yan Wang, Ruslana G. Tytarenko, MS, Eileen Boyle, Christopher Wardell, PhD, Pingping Qu, Sharmilan Thanendrarajan, MD, Sandra Susanibar, MD, Naveen Yarlagadda, MD, Maliha Khan, Meera Mohan, MD, Maurizio Zangari, MD, Frits van Rhee, MD PhD, Faith E. Davies, MD, Bart Barlogie, MD PhD, Gareth Morgan, MD, Brian A Walker, PhD

Blood (2018) 132 (Supplement 1): 114.

https://doi.org/10.1182/blood-2018-99-116758

Published: 2018

Journal Articles

Long-Term Follow-up Identifies Double Hit and Key Mutations As Impacting Progression Free and Overall Survival in Multiple Myeloma

Cody Ashby, PhD, Eileen Boyle, Ruslana G. Tytarenko, MS, Hongwei Wang, MS, Adam Rosenthal, MS, Purvi Patel, Yan Wang, Shayu Deshpande, Maria Ortiz, Erin Flynt, Antje Hoering, PhD, Sharmilan Thanendrarajan, MD, Carolina D. Schinke, MD, Maurizio Zangari, MD, Frits van Rhee, MD PhD, Bart Barlogie, MD PhD, Anjan Thakurta, PhD, Gareth Morgan, MD, Brian A Walker, PhD

Blood (2018) 132 (Supplement 1): 110.

https://doi.org/10.1182/blood-2018-99-113045

Published: 2018

Journal Articles

Increased HLA-E Expression Correlates with Early Relapse in Multiple Myeloma

Blood (2018) 132 (Supplement 1): 59.

https://doi.org/10.1182/blood-2018-99-116828

Published: 2018

Journal Articles

Longer Term Follow up of the Â Randomized Phase III Trial SWOG S0777: Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT)

Brian GM Durie, MD, Antje Hoering, PhD, Rachael Sexton, PhD, Muneer H. Abidi, MD, Joshua Epstein, DSc, S. Vincent Rajkumar, MD, Angela Dispenzieri, MD, Stephen P. Kahanic, MD, Mohan C. Thakuri, MD, Frederic J. Reu, MD, Christopher M. Reynolds, MD, Robert Z. Orlowski, MD PhD, Bart Barlogie, MD PhD

Blood (2018) 132 (Supplement 1): 1992.

https://doi.org/10.1182/blood-2018-99-117003

Published: 2018

Journal Articles

African-American Patients with Monoclonal Gammopathy Have a Reduced Risk of Transformation to Clinical Myeloma: Results of a Prospective Study SWOG S0120

Madhav V Dhodapkar, MD, Rachael Sexton, PhD, Antje Hoering, PhD, Bart Barlogie, MD PhD, Robert Z. Orlowski, MD PhD

Blood (2018) 132 (Supplement 1): 1877.

https://doi.org/10.1182/blood-2018-99-119634

Published: 2018

Journal Articles

Baseline and on-Treatment Bone Marrow Microenvironments Predict Myeloma Patient Outcomes and Inform Potential Intervention Strategies

Blood (2018) 132 (Supplement 1): 1882.

https://doi.org/10.1182/blood-2018-99-113169

Published: 2018

Journal Articles

Sequential Improvements in the Outcome of Autologous Stem Cell Transplantation for Multiple Myeloma over Time

Katherine K Nishimura, Brian A Walker, PhD, Adam Rosenthal, MS, Faith E. Davies, MD, Bart Barlogie, MD PhD, Frits van Rhee, MD PhD, Gareth Morgan, MD, Antje Hoering, PhD

Blood (2018) 132 (Supplement 1): 3168.

https://doi.org/10.1182/blood-2018-99-118605

Published: 2018

Journal Articles

Combination of Flow Cytometry and Functional Imaging for Monitoring of Residual Disease in Myeloma

Blood (2018) 132 (Supplement 1): 3185.

https://doi.org/10.1182/blood-2018-99-119249

Published: 2018

Journal Articles

E2F1 Is a Biomarker of Selinexor Resistance in Relapsed/Refractory Multiple Myeloma Patients

Alessandro Lagana, PhD, Seongjee Park, Donna Edwards, Violetta Leshchenko, PhD, Marsha Crochiere, Yosef Landesman, PhD, David Melnekoff, BS,MS, Itai Beno, PhD, Deepak Perumal, PhD, Deepu Madduri, MD, Joshua Richter, Ajai Chari, MD, Hearn Jay Cho, MD, Bart Barlogie, MD PhD, Sundar Jagannath, MD, Joel Dudley, PhD, Samir Parekh, MD

Blood (2018) 132 (Supplement 1): 3216.

https://doi.org/10.1182/blood-2018-99-116500

Published: 2018

Journal Articles

Walking on myeloma

Bart Barlogie, Joshua Richter

Blood (2018) 132 (16): 1724.

https://doi.org/10.1182/blood-2018-07-861096

Published: 2018

NARROW

Total Therapy (TT)-4: A Phase 3 Trial Comparing L-TT4 and S-TT4 and Tandem Auto Transplants in Standard Risk Multiple Myeloma

Sequential Imaging with Diffusion-Weighted Whole-Body MRI (DW-MRI) and PET-CT Identifies Patients at High Risk of Relapse in Multiple Myeloma

Impact of Dexamethasone (Dex) Dose Strength on Outcomes in Newly Diagnosed Multiple Myeloma (NDMM): A Secondary Analysis of SWOG Studies S0777 and S1211

N-Cadherin Stabilizes β-Catenin and Promotes β-Catenin/TCF Transcriptional Activation and Cell Adhesion-Mediated Drug Resistance in Multiple Myeloma

28-Day Metronomic Therapy for Relapsed Refractory Multiple Myeloma

The Role of PHF19 As a Promoter of Tumorigenicity and Therapeutic Target in Multiple Myeloma

Analysis of the Sub-Clonal Structure of Smoldering Myeloma over Time Provides a New Means of Disease Monitoring and Highlights Evolutionary Trajectories Leading to Myeloma

Long-Term Outcome of Total Therapy Regimens: Impact of Molecular Subgroups

Lack of a Spleen Signal on Diffusion Weighted MRI Is Associated with High Tumor Burden and Poor Prognosis in Multiple Myeloma

Global Expression Changes of Malignant Plasma Cells over Time Reveals the Evolutionary Development of Signatures of Aggressive Clinical Behavior

The Mutational Landscape of Primary Plasma Cell Leukemia

Long-Term Follow-up Identifies Double Hit and Key Mutations As Impacting Progression Free and Overall Survival in Multiple Myeloma

Increased HLA-E Expression Correlates with Early Relapse in Multiple Myeloma

Longer Term Follow up of the Â Randomized Phase III Trial SWOG S0777: Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT)

African-American Patients with Monoclonal Gammopathy Have a Reduced Risk of Transformation to Clinical Myeloma: Results of a Prospective Study SWOG S0120

Baseline and on-Treatment Bone Marrow Microenvironments Predict Myeloma Patient Outcomes and Inform Potential Intervention Strategies

Sequential Improvements in the Outcome of Autologous Stem Cell Transplantation for Multiple Myeloma over Time

Combination of Flow Cytometry and Functional Imaging for Monitoring of Residual Disease in Myeloma

E2F1 Is a Biomarker of Selinexor Resistance in Relapsed/Refractory Multiple Myeloma Patients

Walking on myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only